A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
← catalyst calendarNCT05730036 · readout in 2,435 d
Sponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
410estimated
Sites
159
Countries
Australia, Belgium, Brazil +15
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-09-18 | actual | When the study began enrolling |
| Primary completion | 2033-04-19 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2033-04-19 | estimated | The whole study's end, after follow-up |
| First posted | 2023-02-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Relapsed Refractory Multiple Myeloma (RRMM)
Interventions
- Drug: Linvoseltamab — also filed as REGN5458, Lynozyfic™
- Drug: Elotuzumab — also filed as Empliciti
- Drug: Pomalidomide — also filed as Pomalyst
- Drug: Dexamethasone — also filed as Decadron
Primary outcome
what the primary-completion date above is the date OFProgression Free Survival (PFS) per International Myeloma Working Group (IMWG) response criteria determined by Independent Review Committee (IRC) in CD38 antibody exposed participants
measured Up to approximatively 5 years
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed